Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHEMORAD trial for high-risk muscle-invasive bladder cancer
NL-OMON27865Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cisplatin in bladder cancer and transitional cell carcinoma of the bladder (TCC), sponsored by Netherlands Cancer Institute. Primary endpoints: Bladder-preservation rate and No evidence of disease at 12 months follow-up. Planned start Oct 2015; status: not yet recruiting.
02
Drugs
cisplatin
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on NL-OMON27865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27865.